Octave® Bioscience Continues Commercial Momentum with Addition of Accomplished CFO Marcel Konrad
07 Agosto 2024 - 8:00AM
Business Wire
Octave® Bioscience, a leading precision care company
transforming the management of multiple sclerosis (MS) and other
neurodegenerative diseases, today announced the appointment of
Marcel Konrad as Chief Financial Officer. Marcel brings a
distinguished track record in scaling high-growth therapeutic and
diagnostic companies to Octave as the company enters a pivotal
phase of commercial expansion.
The addition of Marcel follows several new appointments of
proven commercial leaders, including CEO Doug Biehn, Chief Revenue
Officer Jeron Evans, and Chief Access Officer Debbie Ledet.
“Marcel’s ability to build and scale high-performing financial
organizations aligns perfectly with Octave’s ambitious growth
trajectory,” said Doug Biehn, CEO of Octave. “His leadership will
be invaluable as we expand our market reach, deepen customer
relationships, and deliver exceptional value to patients and
healthcare providers.”
Marcel has decades of experience as a growth-focused financial
executive who has rapidly scaled innovative companies and built
world-class teams. Prior to joining Octave, Marcel held several
leadership positions in a range of companies in both therapeutics
and clinical diagnostics such as Novartis, Santen, CareDx, and most
recently Medexus Pharmaceuticals, a publicly traded innovative
specialty pharmaceutical company for rare diseases.
"Octave is at an important inflection point as the company takes
its commercial efforts to a new level of growth and scale, and I’m
delighted to be part of its next chapter,” said Marcel Konrad. “I’m
inspired by Octave’s mission to become the leader in precision care
for neurodegenerative diseases, humbled to work with such a highly
engaged and successful Board, and excited to be part of an
experienced, collaborative team that will deliver on our
mission.”
Brook Byers, Octave Board member, visionary life sciences
investor and founding member of Kleiner Perkins Caufield &
Byers commented, “Marcel is a credible leader who has built great
teams, and has a proven ability to drive and scale large
businesses. Octave is uniquely positioned to help people with MS
and other neurodegenerative conditions with its highly
differentiated Precision Care solution, and bringing on leaders
like Marcel will help the company accelerate its growth and patient
impact.”
This leadership expansion comes at an important growth phase for
the company when Octave is demonstrating rapid provider adoption
and repeat usage, expanding its scientific and clinical evidence,
deepening strategic partnerships with Pharma companies to
accelerate drug development and market differentiation, and
providing health plans a value-based solution to improve health
outcomes and reduce costs.
About Octave® Bioscience, Inc.
Octave® Bioscience, Inc. has developed the industry’s
first comprehensive precision care solution for neurodegenerative
diseases, starting with multiple sclerosis (MS). Octave’s Precision
Care Solution addresses biological, imaging, and clinical insights
to accurately and objectively measure disease activity,
progression, and severity, allowing for better management of
complex and high-cost neurodegenerative diseases. Octave’s
Precision Care Solution is now in use in leading MS centers of
excellence, including 10 of the top 20 MS COE in the US, academic
centers, and high-volume independent clinics across the U.S. The
company has also developed partnerships with leading pharmaceutical
companies and health plans nationwide, and is also expanding into
Parkinson’s with R&D work funded by The Michael J. Fox
Foundation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240806687166/en/
Brian Grancagnolo Deputy Practice Director & SVP, Healthcare
at Hill & Knowlton brian.grancagnolo@hillandknowlton.com